STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANGO
  4. [Form 4] ANGIODYNAMICS INC Insider Trading Activity

AngioDynamics Inc (ANGO) CFO performance shares vest, tax withheld

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AngioDynamics Inc EVP and CFO Stephen A. Trowbridge reported equity award activity related to performance share units granted on July 19, 2023. Based on performance metrics and relative total shareholder return, 16,296 shares of Common Stock vested and were issued from a 57,381-unit target grant, with the remaining units forfeited. To satisfy related tax withholding obligations, 8,319 shares were withheld at $13.82 per share.

Positive

  • None.

Negative

  • None.
Insider Trowbridge Stephen A
Role EVP and CFO
Type Security Shares Price Value
Exercise Performance Right F3 57,381 $0.00 $0.00
Exercise Common Stock F1 16,296 $0.00 $0.00
Tax Withholding Common Stock F2 8,319 $13.82 $115K
Holdings After Transaction: Performance Right — 0 shares (Direct); Common Stock — 305,796 shares (Direct)
Footnotes (3)
  1. F1. This acquisition of 16,296 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
  2. F2. The exempt disposition of 8,319 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
  3. F3. On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
Performance share units target grant 57,381 units Target performance share units granted on July 19, 2023
Common Stock issued from PSUs 16,296 shares Shares of Common Stock issued to the reporting person under this grant
Shares withheld for taxes 8,319 shares Shares of Common Stock withheld to satisfy tax withholding obligations on vesting
Tax withholding price $13.82 per share Price used for tax-withholding disposition of 8,319 shares of Common Stock
Performance earnout range 0%–200% of target Range of performance share units that could be earned based on metrics
performance share units financial
"represents shares acquired through the vesting and settlement of performance share units"
Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.
total shareholder return financial
"based on total shareholder return relative to a peer group of companies"
Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.
tax withholding obligations financial
"made to satisfy tax withholding obligations in connection with the pre-determined vesting"
vesting and settlement financial
"shares acquired through the vesting and settlement of performance share units granted"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What equity award vested for AngioDynamics (ANGO) CFO Stephen A. Trowbridge?
Stephen A. Trowbridge received 16,296 shares of AngioDynamics Common Stock through the vesting and settlement of performance share units granted on July 19, 2023. These shares were earned based on specified performance metrics and relative total shareholder return over a multi‑year period.

What was the original performance share unit grant reported for AngioDynamics (ANGO)?
The reporting person received a target grant of 57,381 performance share units on July 19, 2023. Between 0% and 200% of this target could be earned, depending on achievement of performance metrics for fiscal years 2024, 2025 and 2026 and relative total shareholder return.

How many AngioDynamics (ANGO) shares were withheld to cover taxes in this Form 4?
An exempt disposition of 8,319 shares of Common Stock was made at $13.82 per share to satisfy tax withholding obligations. This withholding was tied to the pre-determined vesting of shares underlying the performance share units granted on July 19, 2023.

Over what period were AngioDynamics (ANGO) performance metrics measured for this award?
The award’s performance share units were earned based on metrics for fiscal years 2024, 2025 and 2026. In addition, up to 20% of total shares earned could be adjusted based on total shareholder return relative to a peer group over a three‑year performance period.

Were the reported AngioDynamics (ANGO) transactions made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5‑1 checkbox is not marked as affirmative, so these transactions are not affirmatively characterized as made under a Rule 10b5‑1 trading plan. The footnotes describe vesting, performance measurement and tax withholding, but do not reference any such plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Trowbridge Stephen A
(Last)(First)(Middle)
14 PLAZA DRIVE
(Street)
LATHAM NEW YORK 12110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP and CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/22/2026M16,296(1)A$0314,115D
Common Stock07/22/2026F8,319(2)D$13.82305,796D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Right(3)07/22/2026M57,381 (3) (3)Common Stock57,381$00D
Explanation of Responses:
1. This acquisition of 16,296 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
2. The exempt disposition of 8,319 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
3. On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
/s/ Lawrence T. Weiss, as Attorney in Fact07/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR